Le Bonheur joins REGEN-COV trial for pediatric COVID-19 treatment

While children infected with COVID-19 are less likely to develop severe illness compared to adults, not enough data exists to determine how they respond to various available treatments. Children with pre-existing conditions who are unvaccinated are a vulnerable population. If infected, they may experience severe symptoms than can lead to hospitalization and death.

Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center (UTHSC) are currently enrolling pediatric volunteers in a clinical trial to understand how they may respond to Regeneron’s investigational antibody medicine, REGEN-COV, which has been approved for emergency use.

Recruiting participants quickly when they first test positive remains critical.

REGEN-COV is another potential tool in the fight against COVID-19 that we can use for children with high-risk conditions, such as heart and lung disease or obesity, who are infected with the virus and have some symptoms but are not sick enough to require hospitalization.

Sandy Arnold, principal investigator for the REGEN-COV trial and Le Bonheur chief of Pediatric Infectious Diseases.

Le Bonheur is currently recruiting volunteers ages 0 to 17 years with at least one risk factor, who have tested
positive within the last three days. Visit www.lebonheur.org/research/clinical-trials to learn more about the COVID-19 clinical trial and how to enroll.

Help us provide the best care for kids.

Le Bonheur Children's Hospital depends on the generosity of friends like you to help us serve 250,000 children each year, regardless of their family’s ability to pay. Every gift helps us improve the lives of children.

Donate Now
Continue Reading This Issue: